Anti-Cancer Drug Design

Virus-detected enzyme prodrug therapy using CB1954
pp. 461-472(12)
Authors: Grove J.; Searle P.; Weedon S.; Green N.; McNeish I.; Kerr D.

Antitumour prodrug development using cytochrome P450 (CYP) mediated activation
pp. 473-486(14)
Authors: Patterson L.; McKeown S.; Robson T.; Gallagher R.; Raleigh S.; Orr S.

Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity
pp. 487-497(11)
Authors: Lee H.; Wilson W.; Denny W.

Camptothecin delivery systems: the utility of amino acid spacers for the conjugation of camptothecin with polyethylene glycol to create prodrugs
pp. 499-506(8)
Authors: Conover C.; Greenwald R.; Pendri A.; Shum K.

Intensely cytotoxic anthracycline prodrugs: galactosides
pp. 507-515(9)
Authors: Bakina E.; Farquhar D.

Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT)
pp. 517-538(22)
Authors: Niculescu-Duvaz I.; Friedlos F.; Niculescu-Duvaz D.; Davies L.; Springer C.

Synthesis and antitumor activities of amino acid prodrugs of amino-combretastatins
pp. 539-548(10)
Authors: Ohsumi K.; Hatanaka T.; Nakagawa R.; Fukuda Y.; Morinaga Y.; Suga Y.; Nihei Y.; Ohishi K.; Akiyama Y.; Tsuji T.